This diabetes drug may lower the risk of cancer; uncovering the hidden link between blood sugar and tumour growth
Metformin, a common type 2 diabetes medication, is being investigated for its potential anti-cancer effects. Research suggests it may inhibit cancer cell growth and suppress tumor development through various biological pathways. While observational studies show promising correlations, clinical trials are ongoing to confirm its efficacy as an adjuvant cancer treatment.
Metformin, a common type 2 diabetes medication, is being investigated for its potential anti-cancer effects. Research suggests it may inhibit cancer cell growth and suppress tumor development through various biological pathways. While observational studies show promising correlations, clinical trials are ongoing to confirm its efficacy as an adjuvant cancer treatment.
